# Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer

> **NCT00005655** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 39 (actual)

## Conditions studied

- Kidney Neoplasm
- Lung Neoplasm
- Sarcoma
- Breast Neoplasm

## Interventions

- **BIOLOGICAL:** rh IL-12
- **BIOLOGICAL:** rh IL-2

## Key facts

- **NCT ID:** NCT00005655
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-04-28
- **Primary completion:** 2010-10-06
- **Final completion:** 2017-03-02
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005655, "Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*